Navigation Links
Researcher, magnet lab receive $2 million grant to target tuberculosis
Date:1/17/2008

TALLAHASSEE, Fla. -- About 5,000 people around the world die from tuberculosis every day, but no effective new drugs have been developed to combat it in 40 years. Researchers at the National High Magnetic Field Laboratory at Florida State University hope to change that through research made possible by a $2-million grant from the National Institutes of Health.

The award will make it possible for Timothy A. Cross, the Earl Frieden Professor of Chemistry and Biochemistry at FSU, and his team to work toward arming drug developers with a map of the proteins on the bacterias surface that are vital for infection.

Because it isnt often seen in the news in the United States, TB often is overlooked, but it remains one of the globes most deadly infectious diseases. The bacterial infection primarily attacks the lungs, causing 2 million deaths around the world each year. Many of the worlds poor are among its victims, and researchers have raised the alarm about drug-resistant strains of the infection, which, according to the Centers for Disease Control, now account for almost one in five new TB cases.

Some potential new treatments for TB already are being researched, said Cross, who also directs the magnet labs Nuclear Magnetic Resonance program, but there is no knowing if those treatments will survive clinical trials.

Trying to treat so much of the world with the same pharmaceuticals is one of the best ways to develop more resistance to treatment, so its important to come at this from as many angles as possible, he said.

Weve done a preliminary study that shows our work is viable, and we have a lot of preliminary data, Cross said of the research plan, expected to take five years to execute. His team, collaborating with the University of Kansas, the University of Alabama and Case Western Reserve University, will use the magnet labs sophisticated 900 megahertz magnet, as well as other resources, to conduct its research.

Cross thinks the eventual development of a new family of TB drugs could attack the disease in a new and more effective way. He explained that a specific set of proteins appears to be important to TBs ability to attack the body. His team will identify the target proteins that allow bacteria to infect lung tissue. When a drug binds to one of these proteins, it can render the protein ineffective, shutting down its ability to do harm.

We ought to be able to solve the molecular structure of these drug targets, he said. If you know the shape of the protein, then you can design a drug that can bind to it specifically. Getting detailed information about the correct drug target makes it far easier for the pharmaceutical companies to develop safer, more effective treatment.

There has been a lot of interest in our proposal, Cross said, adding, The quality of the graduate students here at FSU made the difference for us. Without a quality research team like this one, this project goes nowhere and our chance of funding work this important would have been zero.


'/>"/>

Contact: Timothy A. Cross
cross@magnet.fsu.edu
850-644-0917
Florida State University
Source:Eurekalert  

Related medicine news :

1. Society of Cardiovascular Magnetic Resonance chooses open access
2. Transcranial magnetic stimulation: An effective treatment for depression
3. Penn research shows transcranial magnetic stimulation effective in treating major depression
4. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
5. A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging
6. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
7. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
8. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
9. Novadaqs SPY System receives clearance for use in organ transplant surgery
10. Philadelphia Policeman Helps Amputee Receive Power Wheelchair from The Scooter Store
11. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher, magnet lab receive $2 million grant to target tuberculosis
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: